New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Lawrence Guiheen Biography and Net Worth

Director of ADMA Biologics

Mr. Guiheen became a director of the Company in July 2012 with over 35 years of experience in Healthcare Industry. He is currently the Chairman of the Company’s Governance and Nominations Committee and a member of the Company’s Audit Committee and Compensation Committee. Prior to retiring in March 2022, Mr. Guiheen was Executive Vice President of Wellstat Management and Chief Executive Officer of Wellmond Therapeutics (November 2019 until March 2022). Wellmond Therapeutics is a start-up pharmaceutical company located in Rockville, MD and was developing drug candidates in oncology supportive care and treatments for diseases and conditions involving mitochondrial and cellular energy disorders or failures. In addition, Mr. Guiheen has over 25 years of experience in the blood and plasma industry. From July 2013 to November 2019, Mr. Guiheen served as Chief Commercial Officer of Kedrion Biopharma, Inc., based in Barga, Italy and Fort Lee, New Jersey. Kedrion markets therapies globally for hemophilia, hemolytic disease of the newborn, immune and neurological disorders. Prior to July 2013, Mr. Guiheen was principal of Guiheen and Associates, a consulting group that specialized in biopharmaceutical, pharmaceutical and medical device commercialization. Before July 2011, Mr. Guiheen was with Baxter Healthcare Corporation for over 30 years. Most recently he held the positions of General Manager Global Hemophilia Franchise (from December 2010 to July 2011), President of Global BioPharmaceuticals for Baxter Healthcare’s BioScience Division (March 2010 to December 2010) and President of BioPharmaceuticals US (January 1998 to March 2010). Mr. Guiheen had been a member of the BioScience Senior Management Team for over 14 years and has extensive experience leading global and domestic commercial organizations in the plasma and recombinant therapies. Mr. Guiheen is past Chairman of the Global Board of Directors for the Plasma Proteins Therapeutics Association (PPTA) and a past member of the Board of Directors of California Healthcare Institute (CHI). Mr. Guiheen holds a Bachelor of Arts degree in Business Administration from Rutgers University. Mr. Guiheen was chosen to serve on the Board of Directors because of his extensive experience in the plasma and pharmaceutical industries.

What is Lawrence P. Guiheen's net worth?: The estimated net worth of Lawrence P. Guiheen is at least $3.28 million as of September 9th, 2024. Mr. Guiheen owns 153,941 shares of ADMA Biologics stock worth more than $3,277,404 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Guiheen may own. Learn More about Lawrence P. Guiheen's net worth.
How do I contact Lawrence P. Guiheen?: The corporate mailing address for Mr. Guiheen and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]. Learn More on Lawrence P. Guiheen's contact information.
Has Lawrence P. Guiheen been buying or selling shares of ADMA Biologics?: Lawrence P. Guiheen has not been actively trading shares of ADMA Biologics within the last three months. Most recently, Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a transaction totalling $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. Learn More on Lawrence P. Guiheen's trading history.
Who are ADMA Biologics' active insiders?: ADMA Biologics' insider roster includes Steve Elms (Director), Bryant Fong (Director), Adam Grossman (Co-Founder, President, CEO & Director), Jerrold Grossman (Director), Lawrence Guiheen (Director), Young Kwon (Director), and Brian Lenz (CFO). Learn More on ADMA Biologics' active insiders.
Are insiders buying or selling shares of ADMA Biologics?: During the last year, insiders at the biotechnology company sold shares 9 times. They sold a total of 1,206,795 shares worth more than $13,223,289.83. The most recent insider tranaction occured on September, 9th when Director Lawrence P Guiheen sold 9,000 shares worth more than $166,230.00. Insiders at ADMA Biologics own 3.7% of the company. Learn More about insider trades at ADMA Biologics.
Information on this page was last updated on 9/9/2024.

Lawrence P. Guiheen Insider Trading History at ADMA Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Sell	9,000	$18.47	$166,230.00	153,941
2/11/2020	Buy	20,000	$3.50	$70,000.00	70,000
5/17/2019	Buy	25,000	$4.00	$100,000.00	50,000
3/16/2015	Buy	1,000	$7.96	$7,960.00

Lawrence P. Guiheen Buying and Selling Activity at ADMA Biologics

ADMA Biologics Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Today's Range

Now: $21.29

$20.87

$21.70

50 Day Range

MA: $18.72

$15.62

$22.62

2 Week Range

Now: $21.29

$3.60

$23.64

Volume

645,461 shs

Average Volume

3,636,393 shs

Market Capitalization

$5.03 billion

P/E Ratio

76.04

Dividend Yield

N/A

Beta

0.64